Stock Market & Financial Investment News

News Breaks January 4, 2013 18:23 EDT PFE, ENDP Pfizer, Endo Pharmaceuticals to pay $18.17M each to Texas in Medicaid case Texas Attorney General Greg Abbott announced that two civil Medicaid fraud settlements secured by the Attorney General’s Office will yield more than $36M for the state, and the settlement agreements announced resolve the state’s Medicaid fraud claims against Pfizer (PFE) and Endo Pharmaceuticals (ENDP). Under the agreements, the state will recover $18.17M each from Pfizer and Endo Pharmaceuticals. Reference Link News For PFE;ENDP From The Last 14 Days Check below for free stories on PFE;ENDP the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. 1 | 2 | all recent news | >> May 17, 2013 11:53 EDT ENDP Options with decreasing implied volatility: SGMO ARNA CSC ENDP Subscribe for More Information May 16, 2013 10:03 EDT ENDP On The Fly: Analyst Upgrade Summary Subscribe for More Information 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:27 EDT ENDP Endo Health upgraded to Buy from Neutral at Buckingham Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. May 13, 2013 09:27 EDT ENDP Endo Health downgraded to Market Perform from Outperform at William Blair 09:25 EDT ENDP On The Fly: Pre-market Movers Subscribe for More Information 09:04 EDT ENDP Endo Health falls 4.8% Endo Health is down 4.8%, or $1.67, to $33.30 08:13 EDT ENDP Endo Health price target lowered to $31 from $35 at Susquehanna Subscribe for More Information 07:49 EDT ENDP FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. 07:45 EDT ENDP Endo Health price target lowered to $36 from $42 at Stifel Subscribe for More Information 07:32 EDT ENDP Endo Health downgraded to Sell from Neutral at Lazard Capital Subscribe for More Information 07:20 EDT ENDP Endo Health price target lowered to $37 from $47 at Jefferies Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated. 06:48 EDT ENDP Endo Health downgraded to Fair Value from Buy at CRT Capital Subscribe for More Information May 10, 2013 16:59 EDT ENDP Endo Health says FDA denial could cut FY13 adjusted EPS by 55c Subscribe for More Information 16:29 EDT PFE On The Fly: Closing Wrap Subscribe for More Information 15:45 EDT ENDP Endo Health trading halted, pending news 15:44 EDT ENDP Endo Health denied petition to block Opana ER generics Subscribe for More Information 12:31 EDT PFE On The Fly: Midday Wrap Subscribe for More Information 11:48 EDT PFE Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 09:21 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 1 | 2 | all recent news | >> Sign up for a free trial to see the rest of the stories you've been missing.